IP Library Granted Patent US 10,323,269
Granted Patent B2
US 10,323,269 · App. 15/440,815 · Granted Jun 18, 2019

Selective oxidation of 5-methylcytosine by TET-family proteins

Inventors: Anjana Rao (La Jolla, CA); Mamta Tahiliani (New York, NY); Kian Peng Koh (Jamaica Plain, MA); Suneet Agarwal (Belmont, MA); Aravind Iyer (Bethesda, MD)
Assignees: THE CHILDREN'S MEDICAL CENTER CORPORATION; THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES
C12Q1/6827C12N5/0018C12N5/0607C12N5/0637C12N5/0696C12N9/0071C12N15/873C12Q1/26C12Q1/6806C12Q1/6869C12Q1/6886G01N33/5011G01N33/5308G01N33/57426G01N33/57484G01N33/57496C12N2501/15C12N2501/602C12N2501/603C12N2501/604C12N2501/606C12N2501/70C12N2501/71C12N2501/999C12N2506/1307C12N2506/1353C12N2510/00C12Q2600/154G01N2500/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,323,269
App. No.
15/440,815
Granted
Jun 18, 2019
Kind
B2
Abstract

The present invention provides for novel methods for regulating and detecting the cytosine methylation status of DNA. The invention is based upon identification of a novel and surprising catalytic activity for the family of TET proteins, namely TET1, TET2, TET3, and CXXC4. The novel activity is related to the enzymes being capable of converting the cytosine nucleotide 5-methylcytosine into 5-hydroxymethylcytosine by hydroxylation.

Claims (16)

1. A method comprising contacting with, or delivering to, a human T

cell an effective 5-methylcytosine to 5-hydroxymethylcytosine converting amount of an enzyme or a fragment thereof that oxidizes at least one methylated DNA base.

2. The method of claim 1 , wherein the human T cell is isolated.

3. The method of claim 2 , wherein the human T cell is a purified human CD4+ T cell.

4. The method of claim 1 , further comprising contacting with, or delivering to, the human T cell a composition comprising at least one cytokine, growth factor, activating reagent, or combination thereof.

5. The method of claim 4 , wherein the composition comprises the at least one cytokine, wherein the at least one cytokine comprises TGF-ß.

6. The method of claim 1 , wherein the enzyme or fragment thereof comprises a purified dioxygenase.

7. The method of claim 6 , wherein the purified dioxygenase comprises a catalytically active TET family enzyme, a functional TET family derivative, a TET catalytically active fragment thereof, or any combination thereof.

8. The method of claim 1 , wherein the method increases expression of FOXP3 in the human T cell.

9. The method of claim 1 , wherein the method stabilizes expression of FOXP3 in the human T cell.

10. The method of claim 1 , wherein the contacting with or the delivering to converts a 5-methylcytosine residue in the human T cell to a modified base.

11. The method of claim 10 , wherein the modified base is formed by more than one oxidation reaction.

12. The method of claim 10 , wherein the modified base comprises a 5-hydroxymethylcytosine residue.

13. The method of claim 1 , wherein the method comprises contacting the human T cell with the enzyme or fragment thereof.

14. The method of claim 1 , wherein the method comprises delivering the enzyme or fragment thereof to the human T cell.

15. The method of claim 1 , wherein the enzyme or fragment thereof comprises TETI, TET2, TET3, CXXC4, or a catalytically active fragment of any of these.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 14, 2017
From: IYER, ARAVIND
To: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Reel/Frame 043585/0255 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 6, 2017
From: RAO, ANJANA; TAHILIANI, MAMTA; KOH, KIAN PENG
To: IMMUNE DISEASE INSTITUTE, INC.
Reel/Frame 043506/0504 →
MERGER Recorded Sep 6, 2017
From: IMMUNE DISEASE INSTITUTE, INC.
To: THE CHILDREN'S HOSPITAL CORPORATION
Reel/Frame 043506/0508 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 6, 2017
From: THE CHILDREN'S HOSPITAL CORPORATION
To: CHILDREN'S MEDICAL CENTER CORPORATION
Reel/Frame 043506/0535 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 6, 2017
From: AGARWAL, SUNEET
To: CHILDREN'S MEDICAL CENTER CORPORATION
Reel/Frame 043506/0539 →
Continuity (8)
Continuation 15341344 · Nov 2, 2016
Continuation 15193796 · Jun 27, 2016
Continuation 13795739 · Mar 12, 2013
Continuation 13120861
Provisional Application 61121844 · Dec 11, 2008
Provisional Application 61100995 · Sep 29, 2008
Provisional Application 61100503 · Sep 26, 2008
Related Publication 20180119113A1 · May 3, 2018
Cited By (5)
US 12,291,742 US 12,331,346 US 12,338,489 US 12,467,082 US 12,630,866